Combining Baseline 18F-FDG PET/CT-based Metabolically Active Tumor Volume and Early Detection of Non-Response Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer

0info:eu-repo/semantics/nonPublishe

Serial 18F-FDG PET/CT for early and late metabolic response assessments during capecitabine and sorafenib treatment in metastatic colorectal cancer patients

0info:eu-repo/semantics/publishe

Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients

0info:eu-repo/semantics/publishe

Baseline Cell-free DNA (cfDNA) and Metabolic Tumor Volume (MTV) Independently Predict Outcome in Metastatic Chemorefractory Colorectal Cancer (mCRC)

0info:eu-repo/semantics/nonPublishe

Development and Validation of a Prognostic Score for Overall Survival Integrating Baseline Metabolically Active Tumor Volume measured by 18F-FDG PET/CT and Clinical Factors for Metastatic Colorectal Cancer Patients

0info:eu-repo/semantics/nonPublishe

FDG PET/CT based molecular imaging of tumour induced osteomalacia using a Gallium-68 labeled octreotide analogue

0info:eu-repo/semantics/nonPublishe

Lowering threshold to 15% for early metabolic response assessment using 18F-FDG PET/CT in metastatic colorectal cancer: results from prospective studies with external validation cohort

0info:eu-repo/semantics/publishe

Just rinopharyngitis ?

0info:eu-repo/semantics/nonPublishe

Combination of MATV and Early Metabolic Response Significantly Improves Outcome Prediction in Metastatic Colorectal Cancer: results from prospective development and external validation cohorts

0info:eu-repo/semantics/publishe

Baseline whole body Metabolic Tumor Volume: validation of a new prognostic imaging biomarker in metastatic colorectal cancer

0info:eu-repo/semantics/publishe